Your browser doesn't support javascript.
loading
TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.
Mayer, Klaus; Baumann, Anna-Lena; Grote, Michael; Seeber, Stefan; Kettenberger, Hubert; Breuer, Sebastian; Killian, Tobias; Schäfer, Wolfgang; Brinkmann, Ulrich.
Affiliation
  • Mayer K; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. klaus.mayer.km1@roche.com.
  • Baumann AL; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. annalenabaumann@web.de.
  • Grote M; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. michael.grote@roche.com.
  • Seeber S; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. stefan.seeber@roche.com.
  • Kettenberger H; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. hubert.kettenberger@roche.com.
  • Breuer S; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. sebastian.breuer@roche.com.
  • Killian T; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. tobias.killian@roche.com.
  • Schäfer W; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. wolfgangschaefer@onlinehome.de.
  • Brinkmann U; Roche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, D82377 Penzberg, Germany. ulrich.brinkmann@roche.com.
Int J Mol Sci ; 16(11): 27497-507, 2015 Nov 17.
Article de En | MEDLINE | ID: mdl-26593903
ABSTRACT
TriFabs are IgG-shaped bispecific antibodies (bsAbs) composed of two regular Fab arms fused via flexible linker peptides to one asymmetric third Fab-sized binding module. This third module replaces the IgG Fc region and is composed of the variable region of the heavy chain (VH) fused to CH3 with "knob"-mutations, and the variable region of the light chain (VL) fused to CH3 with matching "holes". The hinge region does not contain disulfides to facilitate antigen access to the third binding site. To compensate for the loss of hinge-disulfides between heavy chains, CH3 knob-hole heterodimers are linked by S354C-Y349C disulphides, and VH and VL of the stem region may be linked via VH44C-VL100C disulphides. TriFabs which bind one antigen bivalent in the same manner as IgGs and the second antigen monovalent "in between" these Fabs can be applied to simultaneously engage two antigens, or for targeted delivery of small and large (fluorescent or cytotoxic) payloads.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Immunoglobuline G / Fragments Fab d'immunoglobuline / Anticorps bispécifiques Limites: Humans Langue: En Journal: Int J Mol Sci Année: 2015 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Immunoglobuline G / Fragments Fab d'immunoglobuline / Anticorps bispécifiques Limites: Humans Langue: En Journal: Int J Mol Sci Année: 2015 Type de document: Article Pays d'affiliation: Allemagne